246 related articles for article (PubMed ID: 25854586)
1. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.
Md Yusof MY; Vital EM; Das S; Dass S; Arumugakani G; Savic S; Rawstron AC; Emery P
Ann Rheum Dis; 2015 Sep; 74(9):1734-8. PubMed ID: 25854586
[TBL] [Abstract][Full Text] [Related]
2. A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis.
Arnold J; Vital EM; Dass S; Aslam A; Rawstron AC; Savic S; Emery P; Md Yusof MY
Front Immunol; 2021; 12():803175. PubMed ID: 35095887
[TBL] [Abstract][Full Text] [Related]
3. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
4. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
Unizony S; Lim N; Phippard DJ; Carey VJ; Miloslavsky EM; Tchao NK; Iklé D; Asare AL; Merkel PA; Monach PA; Seo P; St Clair EW; Langford CA; Spiera R; Hoffman GS; Kallenberg CG; Specks U; Stone JH
Arthritis Rheumatol; 2015 Feb; 67(2):535-44. PubMed ID: 25332071
[TBL] [Abstract][Full Text] [Related]
5. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
[TBL] [Abstract][Full Text] [Related]
6. Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.
Bunch DO; Mendoza CE; Aybar LT; Kotzen ES; Colby KR; Hu Y; Hogan SL; Poulton CJ; Schmitz JL; Falk RJ; Nachman PH; Pendergraft WF; McGregor JG
Ann Rheum Dis; 2015 Sep; 74(9):1784-6. PubMed ID: 25934841
[No Abstract] [Full Text] [Related]
7. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
8. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.
van Dam LS; Oskam JM; Kamerling SWA; Arends EJ; Bredewold OW; Berkowska MA; van Dongen JJM; Rabelink TJ; van Kooten C; Teng YKO
Front Immunol; 2020; 11():566732. PubMed ID: 33384685
[TBL] [Abstract][Full Text] [Related]
9. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease.
Venhoff N; Niessen L; Kreuzaler M; Rolink AG; Hässler F; Rizzi M; Voll RE; Thiel J
Autoimmunity; 2014 Sep; 47(6):401-8. PubMed ID: 24798501
[TBL] [Abstract][Full Text] [Related]
10. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
12. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.
Pendergraft WF; Cortazar FB; Wenger J; Murphy AP; Rhee EP; Laliberte KA; Niles JL
Clin J Am Soc Nephrol; 2014 Apr; 9(4):736-44. PubMed ID: 24626432
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N
Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362
[TBL] [Abstract][Full Text] [Related]
14. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
15. Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.
Bunch DO; McGregor JG; Khandoobhai NB; Aybar LT; Burkart ME; Hu Y; Hogan SL; Poulton CJ; Berg EA; Falk RJ; Nachman PH
Clin J Am Soc Nephrol; 2013 Mar; 8(3):382-91. PubMed ID: 23293123
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L;
Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
[TBL] [Abstract][Full Text] [Related]
17. Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.
Monach PA; Tomasson G; Specks U; Stone JH; Cuthbertson D; Krischer J; Ding L; Fervenza FC; Fessler BJ; Hoffman GS; Ikle D; Kallenberg CG; Langford CA; Mueller M; Seo P; St Clair EW; Spiera R; Tchao N; Ytterberg SR; Gu YZ; Snyder RD; Merkel PA
Arthritis Rheum; 2011 Dec; 63(12):3988-97. PubMed ID: 21953143
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
[TBL] [Abstract][Full Text] [Related]
20. Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.
Chocova Z; Hruskova Z; Mareckova H; Svobodova B; Duskova D; Bednarova V; Jancova E; Rysava R; Tesar V
Clin Rheumatol; 2015 Jan; 34(1):107-15. PubMed ID: 25388644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
